Olanzapine and haloperidol in first episode psychosis: Two-year data

Schizophrenia Research

Volumn 86, Issue 1-3, 2006, Pages 234-243

  Green, A I ^a   Lieberman, J A ^b   Hamer, R M ^c   Glick, I D ^d   Gur, R E ^e   Kahn, R S ^f   McEvoy, J P ^g   Perkins, D O ^h   Rothschild, A J ⁱ   Sharma, T ^j   Tohen, M F ^k,l   Woolson, S ^c   Zipursky, R B ^m  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c IL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^j NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^k ELI LILLY AND COMPANY   (United States)

^l MCLEAN HOSPITAL   (United States)

^m UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

First episode; Haloperidol; Olanzapine; Psychosis; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BIPERIDEN; CHLORAL HYDRATE; CHOLESTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PROCYCLIDINE; PROPRANOLOL; VALPROIC ACID;

ADOLESCENT; ADULT; AGITATED DEPRESSION; AKATHISIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYNDROME; HUMAN; INVOLUNTARY MOVEMENT; LIVER FUNCTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; INTERNATIONAL COOPERATION; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 33747398701     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.06.021     Document Type: Article

References (30)

1. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
2. Birchwood M., Todd P., and Jackson C. Early intervention in psychosis: the critical period hypothesis. Br. J. Psychiatr., Suppl. 172 33 (1998) 53-59
3. Czernansky J.G., Mahmoud R., Brenner R., and Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346 1 (2002) 16-22
4. Davis J.M., Chen N., and Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60 6 (2003) 553-564
5. Davidson J., Turnbull C.D., Strickland R., Miller R., and Graves K. The Montgomery-Asberg Depression Scale: reliability and validity. Acta Psychiatr. Scand. 73 5 (1986) 544-548
6. Emsley R.A. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr. Bull. 25 (1999) 721-729
7. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM IV-Axis I Disorders (1996), APA Press, Washington, DC
8. Geddes J., Greemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 321 (2000) 1371-1376
9. Green A.I., and Schildkraut J.J. Should clozapine be a first-line treatment for schizophrenia: the rationale for a double-blind clinical trial in first-episode patients. Harv. Rev. Psychiatr. 3 1 (1995) 1-9
10. Gur R.C., Sackeim H.A., and Gur R.E. Classroom seating and psychopathology: some initial data. J. Abnorm. Psychology 85 1 (1976) 122-124
11. Guy W. AIMS. ECDEU Assessment Manual for Psychopharm (1976), NIMH 534-537
12. Haas G.L., Garratt L.S., and Sweeney J.A. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J. Psychiatr. Res. 32 3-4 (1998) 151-159
13. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 2 (1987) 261-276
14. Keefe R.S.E., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Lewine R.R.J., Yurgelun-Todd D.A., Gur R.C., Tohen M., Tollefson G.D., Sanger T.M., Lieberman J.A., and HGDH Research Group. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 161 6 (2004) 985-995
15. Lieberman J.A., Sheitman B., Chakos M., Robinson D., Schooler N., and Keith S. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiological perspective. J. Clin. Psychopharmacol. 18 (1998) 20S-24S
16. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji Z., Koch G., and Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28 5 (2003) 995-1003
17. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M., and HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 160 8 (2003) 1396-1404
18. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S.E., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M., and the HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 62 (2005) 361-370
19. Loebel A.D., Lieberman J.A., Alvir J.M.J., Mayerhoff D.L., Geisler S.H., and Szymanski S.R. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry 149 9 (1992) 1183-1188
20. McEvoy J.P., Hogarty G.E., and Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 48 8 (1991) 739-745
21. McGlashen T.H., and Fenton W.S. Subtype progression and pathopsychologic deterioration in early schizophrenia. Schizophr. Bull. 19 (1993) 71-84
22. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 (1995) 998-1007
23. Robinson D.G., Woerner M.G., Alvir J.M.J., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Bilder R., Goldman R., and Lieberman J.A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 156 4 (1999) 544-549
24. Sanger T.M., Lieberman J.A., Tohen M., Grundy S., Beaslery C., and Tollefson G.D. Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry 156 (1999) 79-87
25. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 212 (1970) 11-19
26. Waddington J.L., Buckley P.F., Scully P.J., Lane A., O'Callaghan E., and Larkin C. Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics?. J. Psychiatr. Res. 32 3-4 (1998) 179-189
27. Woerner M.G., Robinson D.G., Alvir J.M., Sheitman B.B., Lieberman J.A., and Kane J.M. Clozapine as a first treatment for schizophrenia. Am. J. Psychiatry 160 8 (2003) 1514-1516
28. Wyatt R.J. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 17 2 (1991) 325-351
29. Zhang-Wong J., Zipursky R.B., Beiser M., and Bean G. Optimal haloperidol dosage in first-episode psychosis. Can. J. Psychiatry 44 2 (1999) 164-167
30. Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M., McEvoy J., Strakowski S.M., Sharma T., Kahn R., Gur R.E., Tollefson G., Lieberman J.A., and HGDH Research Group. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Brit. J. Psychiatry 187 (2005) 537-543